The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1747
February 2, 2026
View Complete Issue         Table of Contents 2019 
Oral Semaglutide (Wegovy) for Weight Loss
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Oral Semaglutide (Wegovy) for Weight Loss
February 2, 2026 (Issue: 1747)
The FDA has approved an oral tablet formulation of the glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide (Wegovy) for chronic weight management in adults. It is the first oral GLP-1 receptor agonist to be approved in the US for weight...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Oral Semaglutide (Wegovy) for Weight Loss
Article code: 1747a
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.